Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Pharmacyclics, Inc. (NQ: PCYC)
84.70 USD  -3.56 (-4.03%)
Official Closing Price  /  Updated: 4:00 PM EDT, Jun 19, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Pharmacyclics, Inc.
 
< Previous 1 2 3 4 5 6 Next >
Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
Today 17:51 EDT
from PR Newswire
Research Abstracts, Phase 2 Results, and Market Availability of Formulations and Treatments- Research Report on Teva, Forest, Pharmacyclics, Cubist, and Dr. Reddy's
Today 8:00 EDT
Editor Note: For more information about this release, please scroll to bottom Read More
from PR Newswire
Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
June 16, 2013
from PR Newswire
Pharmacyclics Reports First Quarter 2013 Results
May 01, 2013
from PR Newswire
Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
April 24, 2013
from PR Newswire
Free Research Reports on CE, PCYC, RTK and TLAB Issued by the Paragon Report
April 22, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit Read More
from Marketwired News Releases
Pharmacyclics Completes Enrollment of First Phase III Ibrutinib CLL Study - RESONATE™ and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study - SPARK
April 18, 2013
from PR Newswire
Amarin, Pharmacyclics, Anthera Pharma, Star Scientific, and Impax Laboratories Under StockCall's Microscope
April 16, 2013
from PR Newswire
Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
April 11, 2013
from PR Newswire
Free Research Reports on ANAC, GE, OMPI and PCYC Issued by the Paragon Report
April 09, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit Read More
from Marketwired News Releases
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
April 08, 2013
-Nine Ibrutinib Presentations at the American Association of Cancer Research - Read More
from PR Newswire
Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
April 08, 2013
from PR Newswire
Warner Chilcott, Dynavax Technologies, Isis Pharma, United Therapeutics, and Pharmacyclics Under StockCall's Microscope
March 13, 2013
from PR Newswire
Pharmacyclics, Inc. Prices Public Offering of Common Stock
March 08, 2013
from PR Newswire
Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
March 07, 2013
from PR Newswire
Critical Alerts For Qualcomm, CBS, DaVita, O'Reilly Automotive, and Pharmacyclics Released By InvestorsObserver
March 07, 2013
from PR Newswire
Free Research Reports on BIOF, HLF, LOGM and PCYC Issued by the Bedford Report
February 18, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
February 14, 2013
from PR Newswire
Free Research Report on BCE Inc., Diamond Foods, Inc., Cintas Corp., Pharmacyclics, Inc. and Eldorado Gold Corporation
February 13, 2013
from Marketwired News Releases
Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
February 12, 2013
from PR Newswire
Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
February 07, 2013
from PR Newswire
Should Recent Insider Selling on TOL, CVH, SWI and PCYC Matter to You?
December 20, 2012
from Marketwired News Releases
Free Research Reports on AGNC, CRME, PCYC and PEIX Issued by the Bedford Report
December 12, 2012
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
Pharmacyclics® Announces Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) at American Society of Hematology (ASH) Annual Meeting
December 11, 2012
Investigational agent ibrutinib (PCI-32765) demonstrates prolonged progression free survival with a manageable and predictable safety profile in high unmet need indications; relapsed and refractory,... Read More
from PR Newswire
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
December 11, 2012
Data Presented at American Society of Hematology Annual Meeting Read More
from PR Newswire
Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
December 08, 2012
from PR Newswire
Critical Alerts For Amazon.com, Estee Lauder, Kroger, Pharmacyclics, and Zillow Released By InvestorsObserver
December 04, 2012
from PR Newswire
Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
November 05, 2012
from PR Newswire
Pharmacyclics® Triggers Another Significant Milestone Payment for Phase III Chronic Lymphocytic Leukemia Combination Trial
October 15, 2012
from PR Newswire
Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
September 05, 2012
from PR Newswire
< Previous 1 2 3 4 5 6 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here